| 摘要 |
2124461 9311159 PCTABS00022 Human interleukin-8 (IL-8) analogs that are modified in the Glu4Leu5Arg6 region, and have a core structure corresponding to the IL-8(7-51) sequence are provided. These neutrophil binding analogs display altered IL-8 activities that can be exploited for therapeutic and other purposes. Such antagonists include those in which, for example, the Leu5 and/or Arg6 residues are replaced, and in which the Glu4 and/or Leu5 residues are deleted. Also provided are biologically active human interleukin-8 (IL-8) analogs comprising a core sequence that includes IL-8(1-51), IL-8(3-51) or IL-8(4-51). This invention also provides pharmaceutical compositions containing the aforementioned analogs.
|
